
Elegen
Innovation Is Our DNA
- Employees
- 11–50
- Website
- elegenbio.com
- Total Funding
- $35.0M
- Last Round
- $35.0M Series BMay 2024
- Rounds
- 1
About
Elegen is a synthetic biology company that has developed ENFINIA™, the world's only entirely cell-free platform for rapid, high-quality DNA production. Using patented microfluidic synthesis, AI, and robotics, Elegen delivers long, clonal-quality, high-complexity DNA — including linear, plasmid, and IVT-ready formats — in 6 to 8 business days with 99.999% per-base accuracy. Unlike traditional approaches that require bacterial cloning and colony screening, Elegen's cell-free process eliminates bioburden, recombination, and foundry dependencies. ENFINIA DNA serves applications in cell and gene therapy, mRNA vaccines, personalized cancer vaccines, and protein expression, enabling faster and more reliable development of next-generation biologics.
Summary
Elegen is a Healthcare company. It has raised $35.0M in total across 1 round, most recently a $35.0M Series B round in May 2024. Investors include Triatomic Capital and Andreessen Horowitz.
Tech & App Stack
4 technologies & apps tracked
Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.
Funding History
May 2024
Investors
Similar Companies
Largest private manufacturer and distributor of medical-surgical products serving healthcare prov...
Healthcare cost management company providing data analytics and network-based payment solutions t...
American dietary supplements company owning Nature's Bounty, Solgar, and Puritan's Pride brands; ...
China's leading blood products manufacturer
OneOncology empowers oncology practices with advanced tools and capabilities to help physicians d...

World-leading Canadian cannabis company cultivating and selling medicinal and recreational cannab...
